Holen Sie sich die Stockscreener-App
44.05
1.89%
-0.85
Schlusskurs vom Vortag:
$44.90
Offen:
$44.96
24-Stunden-Volumen:
73,080
Relative Volume:
0.09
Marktkapitalisierung:
$1.89B
Einnahmen:
$4.85M
Nettoeinkommen (Verlust:
$-114.75M
KGV:
-13.55
EPS:
-3.25
Netto-Cashflow:
$-100.36M
1W Leistung:
+0.15%
1M Leistung:
+30.58%
6M Leistung:
+137.18%
1J Leistung:
+86.16%
1-Tages-Spanne:
$43.61
$45.08
1-Wochen-Bereich:
$42.00
$45.45
52-Wochen-Spanne:
$13.37
$45.45
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
44.05 | 1.92B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.89 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
728.93 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.69 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
904.77 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.60 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Nothing is Better Than Dianthus Therapeutics Inc (DNTH) stock at the moment - Setenews
27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat
Geode Capital Management LLC Has $9.04 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Can Dianthus Therapeutics Inc. (87E) stock sustain breakout momentum2025 AllTime Highs & Detailed Earnings Play Alerts - Newser
Is Dianthus Therapeutics Inc. (87E) stock a contrarian opportunityWeekly Loss Report & Real-Time Volume Analysis - Newser
Dianthus Therapeutics stock hits 52-week high at 45.0 USD - Investing.com
Can Dianthus Therapeutics Inc. (87E) stock deliver double digit returnsPortfolio Performance Report & Low Drawdown Momentum Trade Ideas - Newser
Will Dianthus Therapeutics Inc. (87E) stock outperform value peersTrade Risk Assessment & Low Risk High Reward Ideas - Newser
Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC - MarketBeat
CapEx per share of Dianthus Therapeutics, Inc. – TRADEGATE:87E - TradingView
DNTH: Advancing two autoimmune therapies with strong clinical data and $525M cash runway - TradingView
Ensign Peak Advisors Inc Invests $2.50 Million in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Stocks of Dianthus Therapeutics Inc (DNTH) are poised to climb above their peers - Setenews
Fed fueled market rally dnth breakout setup and ethereums critical test zone ahead | Fundamental analysis - RichTv
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighShould You Buy? - MarketBeat
Avidity Partners Management LP Reduces Stake in Dianthus Therape - GuruFocus
What analysts say about Dianthus Therapeutics Inc stockStock Buy Signals & Top Analyst Picks Available for Free - earlytimes.in
Dianthus Therapeutics stock hits 52-week high at 43.69 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Dianthus Therapeutics (Nasdaq: DNTH) joins 8th Evercore Healthcare Conference on Dec. 2 - Stock Titan
The Insider Report: Prepare for the Next Dip Buying Opportunity - Benzinga
DNTH SEC FilingsDianthus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wedbush Maintains Dianthus Therapeutics (DNTH) Outperform Recommendation - MSN
How forex fluctuations impact Dianthus Therapeutics Inc. (87E) stockPortfolio Gains Summary & Safe Capital Growth Trade Ideas - newser.com
Why Dianthus Therapeutics Inc. stock remains resilient2025 Short Interest & Real-Time Volume Triggers - newser.com
How Dianthus Therapeutics Inc. (87E) stock performs in easing cyclesCEO Change & Daily Entry Point Alerts - newser.com
How Dianthus Therapeutics Inc. stock reacts to global recession fearsJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com
Views of Wall Street’s Leading Experts on Dianthus Therapeutics Inc - Setenews
Smart tools for monitoring Dianthus Therapeutics Inc.’s price action2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
What analysts say about Dianthus Therapeutics Inc 87E stock - earlytimes.in
How to escape a deep drawdown in Dianthus Therapeutics Inc.Earnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $3,221,132.67 in Stock - Defense World
Candriam S.C.A. Has $4.48 Million Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Dianthus Therapeutics Insider Sold Shares Worth $7,379,887, According to a Recent SEC Filing - MarketScreener
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month High – Here’s Why - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 109,031 Shares - MarketBeat
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 87,507 Shares of Stock - MarketBeat
What dividend safety score for Dianthus Therapeutics Inc. stock2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighWhat's Next? - MarketBeat
Will Dianthus Therapeutics Inc. (87E) stock hit Wall Street targetsWeekly Trend Summary & Real-Time Buy Zone Alerts - newser.com
Can Dianthus Therapeutics Inc. stock hit analyst price targetsEarnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results - Quiver Quantitative
Is Dianthus Therapeutics Inc. (87E) stock a fit for income portfoliosNew Guidance & Safe Entry Point Identification - newser.com
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):